Recurrent Childhood Soft Tissue Sarcoma
21
1
3
17
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 21 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
35%
6 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (21)
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Ex Vivo Drug Sensitivity Testing and Mutation Profiling
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
Trabectedin and Irinotecan for Refractory Pediatric Sarcomas
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas